Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Stock Information for Actinium Pharmaceuticals Inc. (Delaware)
Loading
Please wait while we load your information from QuoteMedia.